Immuron Ltd — Capital/Financing Update 2015

Nov 11, 2015

==> picture [221 x 62] intentionally omitted <==

Immuron Executes U.S. Travelan Sales Agreement with Medico-Mart, Inc.

Thursday 12[th] November 2015 – Melbourne, Australia: Immuron Limited is pleased to announce that the Company has executed a non-exclusive distribution agreement with Medico-Mart, Inc. of Waukesha, Wisconsin. The terms and conditions of the agreement will remain confidential.

Medico-Mart, Inc. specialises in fulfilling the product needs of physician offices, clinics and healthcare organisations throughout the United States.

Medico-Mart was founded in 1935 and is now a leading distribution healthcare company in the U.S. servicing customers across a wide variety of specialist areas including: pediatrics, internal medicine, family practice, travel medicine and occupational medicine. Their coverage ranges from single physician offices to large healthcare organisations.

The President of Medico-Mart, Inc., Jerry Walsh said;

“The introduction of Travelan into our pharmaceutical portfolio will allow us to better serve our travel medicine customers whilst providing Medico-Mart with opportunities for additional business development in the travel market. We look forward to a successful partnership with Immuron.”

Thomas Liquard, CEO of Immuron added;

“Since its creation more than 70 years ago, Medico-Mart has always been at the forefront of the travel medicine market. We are thrilled to add Medico-Mart, a company that clearly understands the value of differentiated travel products like Travelan, to our growing list of partners in the U.S.”

About Immuron

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Company Contact: Immuron US Investor Relations: Thomas Liquard Jon Cunningham Chief Executive Officer RedChip Companies, Inc. AUS Ph: +61 (0)3 9824 5254 US Ph: +1 (407) 644 4256, (ext. 107) thomasliquard@immuron.com jon@redchip.com

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

==> picture [71 x 23] intentionally omitted <==

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Page 2 of 2